Arena Pharmaceuticals (ARNA +4.3%) rallies with the help of a Sunday Bloomberg column discussing...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

Arena Pharmaceuticals (ARNA +4.3%) rallies with the help of a Sunday Bloomberg column discussing potential M&A interest in the drug developer, thanks to recent FDA approval of its Belviq weight-loss drug. Analysts speculate GlaxoSmithKline (currently divesting a diet pill line) or Japan's Eisai (the U.S. launch partner for Belviq) could make a bid. 25.3% of Arena's float was shorted as of June 15.